Document Detail

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.
MedLine Citation:
PMID:  21535447     Owner:  NLM     Status:  Publisher    
Background  Infliximab (IFX) elicits acute severe infusion reactions in about 5% of patients with inflammatory bowel disease (IBD). Aim  To investigate the role of anti-IFX antibodies (Ab) and other risk factors. Methods  The study included all IBD patients treated with IFX at a Danish university hospital until 2010 either continuously (IFX every 4-12 weeks) or episodically (reinitiation after >12 weeks). Anti-IFX Ab were measured using radioimmunoassay. Results  Twenty-five (8%) of 315 patients experienced acute severe infusion reactions. Univariate analysis showed that patients who reacted were younger at the time of diagnosis (19 vs. 26 years, P = 0.013) and at first IFX infusion (28 vs. 35 years, P = 0.012). Furthermore, they more often received episodic therapy (72% vs. 31%, P < 0.001) and logistic regression revealed this as the only significant predictor of reactions (OR 5 [2-13]; P < 0.001). IFX reinitiation after 6 months intermission further increased the risk (OR 8 [3-20], P < 0.001). Most reactions (n = 14, 88%) occurred at 2nd infusion in the 2nd treatment series (P = 0.006). Anti-IFX IgG Ab were highly positive in 19 of 20 patients (95%) shortly after the reactions (median 84 U/mL). Anti-IFX IgG Ab measured prior to the retreatment series were negative in 7 of 11 patients tested (64%). Anti-IFX IgE Ab were negative in all patients with reactions. Conclusions  Acute severe infusion reactions were strongly associated with development of anti-IFX IgG Ab, but not with anti-IFX IgE Ab. The risk was particularly high at the 2nd infusion in retreatment series. Negative anti-IFX Ab before reinitiation did not rule out reactions.
C Steenholdt; M Svenson; K Bendtzen; O Ø Thomsen; J Brynskov; M A Ainsworth
Related Documents :
3875817 - Elevated plasma von willebrand factor levels and arterial occlusive complications assoc...
8237997 - Hypofibrinolysis in patients with hypercoagulability: the roles of urokinase and of pla...
19222477 - Guidelines for the diagnosis and management of disseminated intravascular coagulation. ...
11590527 - Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse t...
9180597 - Disposition of proguanil in thai patients with uncomplicated falciparum malaria.
11874077 - Transvaginal ultrasonography and hysterosonography to monitor endometrial effects in ta...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-5-3
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  -     ISSN:  1365-2036     ISO Abbreviation:  -     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-5-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2011 Blackwell Publishing Ltd.
Department of Medical Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev, Denmark. Biomonitor A/S, Copenhagen, Denmark. Institute for Inflammation Research, University Hospital of Copenhagen, Rigshospitalet, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postpr...
Next Document:  Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-i...